On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the August 2024 CRG meeting. Actions in this consultation include:
- Drospirenone 4mg POP – green (specialist advice), alternative
- Fezolinetant – decision pending, to be reviewed when the NICE TA is published
- High-cost drugs with biosimilars – originator brands to be removed from formulary and replaced with advice to prescribe the best value biosimilar
- Lebrikizumab for atopic dermatitis – red
- Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor – red
- Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B – red
- Tenecteplase for treating acute ischaemic stroke – red
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
This consultation will run for six weeks and closes at 5pm on Thursday 26th September 2024. To take part, visit the consultations page.